Press release
Urothelial Carcinoma Treatment Market Surging to Register 7.8% of CAGR till 2023 | Along with Prominent Players like GlaxoSmithKline plc, Genentech, Novartis AG, Dendreon, Merck KGaA, Eisai Co., etc
Urothelial Carcinoma Treatment Market
Urothelial Carcinoma Treatment Market - Overview
Global urothelial carcinoma treatment market is expected to grow over the forecast period of 2023 and is expected to register a CAGR ~7.8% during the forecast period of 2018–2023.
Urothelial carcinoma is also called as transitional cell carcinoma which is a cancerous tumor of the bladder that can spread to other parts of the body. These are also called as malignant tumors. This tumor can start at any part of the urinary tract. People with bladder cancer may also have similar cancer in other parts of the urinary tract. Hence the urothelial carcinoma treatment market is expected to grow due to increasing prevalence of bladder cancer. Increasing investment in R&D activities to come up with new cancer treatment is also boosting the market for urothelial carcinoma treatment. As various awareness programs are carried out by government and non-government organizations regarding bladder cancer, it is expected to boost the urothelial carcinoma treatment market during the forecast period.
Request for Sample Report at https://www.marketresearchfuture.com/sample_request/6444
Various factors that can hamper the growth of the market are the presence of the generic drug in the market and the high cost of R&D investment for the development of a new drug for treatment.
Competitive Dashboard:
Key players for the global urothelial carcinoma treatment market are GlaxoSmithKline plc
Genentech
Novartis AG
Dendreon
Merck KGaA
Eisai Co.
Sanofi S.A.
Bristol-Myers Squibb.
Check Discount at https://www.marketresearchfuture.com/check-discount/6444
Segmentation:
The global urothelial carcinoma treatment market has been segmented on the basis of types, treatment, and end-users. Based on type the global urothelial carcinoma treatment is segmented into non-invasive and invasive urothelial carcinoma treatment. On basis of treatment, the market is segmented into immunotherapy, radiotherapy, and chemotherapy. Based on end-user the urothelial carcinoma market is segmented into hospital pharmacy, retail pharmacy, and others.
Global Urothelial Carcinoma Treatment Market, by Type
Non-invasive urothelial carcinoma treatment
Invasive urothelial carcinoma treatment
Global Urothelial Carcinoma Treatment Market, by Treatment
Immunotherapy
Radiotherapy
Chemotherapy
Global Urothelial Carcinoma Treatment Market, by End-User
Hospital pharmacy
Retail pharmacy
Others
Regional Analysis:
On a regional basis, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Americas is likely to dominate the urothelial carcinoma treatment market owing to the increasing prevalence of bladder cancer, increasing investment in research and development of new bladder cancer treatment. According to the American cancer society report, about 79030 cases of bladder cancer was reported in 2017 in the US.
Europe is the second largest market for the urothelial carcinoma treatment followed by Asia-Pacific. Due to growing awareness regarding early diagnosis of bladder cancer and developed healthcare infrastructure with increasing prevalence of urothelial cancer. Asia-Pacific shows the fastest growth in the market due to the low cost of R&D. India and China are expected to be the fastest growing market for bladder cancer treatment.
The Middle East and Africa has the lowest market for urothelial carcinoma treatment due to poor medical facilities and lack of technology.
Ask Any Question at https://www.marketresearchfuture.com/enquiry/6444
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Urothelial Carcinoma Treatment Market Surging to Register 7.8% of CAGR till 2023 | Along with Prominent Players like GlaxoSmithKline plc, Genentech, Novartis AG, Dendreon, Merck KGaA, Eisai Co., etc here
News-ID: 1289628 • Views: …
More Releases from Market Research Future
Hydrofluoric Acid Market (CAGR) of 4%, Innovation Imperative Future Proofing You …
Hydrofluoric acid (HF) is a crucial chemical compound with a wide range of applications across various industries. Despite its hazardous nature, it plays an essential role in manufacturing processes, especially in the production of fluorine compounds. The global hydrofluoric acid market has been witnessing steady growth, driven by demand from end-user industries such as oil refining, pharmaceuticals, and electronics.
The Hydrodesulfurization Catalysts Market is projected to register a CAGR of over…
Palm Methyl Ester Derivative Market Size Projected to Grow at 5.92% CAGR, Reachi …
In recent years, the global market for palm methyl ester derivatives has witnessed significant growth, driven by various factors including environmental concerns, technological advancements, and the increasing demand for sustainable alternatives in various industries. Palm methyl ester derivatives, derived from palm oil, have emerged as versatile ingredients with applications spanning across sectors such as cosmetics, pharmaceuticals, lubricants, and more.
The Palm Methyl Ester Derivative Market Size was valued at USD 1.5…
Asia-Pacific Ceramic Tiles Market to Register Highest CAGR Growth of 7.50% by 20 …
The Asia-Pacific ceramic tiles market has been witnessing robust growth, driven by various factors such as increasing investments in residential and commercial construction, renovation activities, and the growing preference for aesthetically pleasing and durable flooring solutions. Countries like China, India, Japan, and South Korea have been leading the market growth, supported by strong manufacturing capabilities, technological advancements, and evolving consumer preferences.
Asia-Pacific Ceramic Tiles Market Size was valued at USD 141.2…
APAC Wallpaper Market to Register Highest CAGR Growth of 8% by 2032: Analysis by …
The APAC wallpaper market has witnessed significant growth in recent years, driven by factors such as rising disposable incomes, expanding construction activities, and growing awareness regarding interior decor. Countries like China, India, Japan, South Korea, and Australia have emerged as key contributors to the region's wallpaper market. Additionally, the increasing adoption of innovative wallpaper designs and patterns is fueling market growth further.
APAC Wallpaper Market Size was valued at USD 0.55…
More Releases for Urothelial
Urothelial Cancer Drugs Market Report Up to 2031
Visongain has published a new report on Urothelial Cancer Drugs Market Report 2021-2031: Forecasts by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, and Adenocarcinoma), by Treatment (Chemotherapy, Immunotherapy). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Urothelial Cancer Drugs market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx…
Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sacituzumab Govitecan (from Gilead Sciences) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.
Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugated to a topoisomerase I inhibitor (SN-38). Trop-2 receptor, a protein frequently expressed in multiple types…
European Urothelial Carcinoma Market Research and Forecast 2020-2026
European urothelial carcinoma market is estimated to grow significantly at a CAGR of around 9.2%, during the forecast period. The growth of the market is attributed to well-developed healthcare infrastructure, significant healthcare expenditure, and growing prevalence and incidence of urothelial carcinoma across many European economies. Sedentary lifestyle such as smoking, consumption of drugs, and alcohol in European countries are the major factors for the growing incidence of urothelial carcinoma among…
Urothelial Carcinoma Treatment Market to Record Study Growth by 2024
Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma…
Urothelial Carcinoma Diagnostics Market Forecast over 2017 – 2025
Urothelial Carcinoma or Transitional Cell Carcinoma encompasses cancer in different parts of urinary tract like kidney, bladder, ureters, and renal pelvis. Bladder tumors account for 90-95% of urothelial carcinoma. Urothelial Carcinoma occur more commonly in men than in women with the ratio of 3:1. Tobacco smoking, Coffee drinking, analgesic abuse, some occupational exposures are the factors that promote urothelial carcinoma. The urothelial carcinoma diagnosis involves the tests that are used…
Urothelial Carcinoma Treatment Market : Trends and Key Developments 2016 - 2024
Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma…
